Netherlands-based Royal Philips has received 510(k) approval from the US Food and Drug Administration (FDA) for its Avalon CL Fetal Monitoring solution (Avalon CL).
Providing mothers more freedom of movement during labor, the solution offers consistent monitoring of the mother and child, without the burden of managing cables.
Philips Healthcare patient care and monitoring solutions CEO Mike Mancuso said: "Conventional fetal monitoring solutions present limitations for physicians and patients alike.
"This latest cableless technology enhances clinician confidence and allows women more flexibility and freedom of movement during labor, which can be very beneficial to the woman and child."
Allowing consistent monitoring while the mother is on the move, the solution is said to continuously measure and transmit fetal heart rate and maternal pulse, uterine activity, and fetal or maternal ECG.
Avalon CL features patented Smart Pulse technology that is developed to automatically detect heart rate coincidence between the maternal pulse and the fetal heart rates, even for twins and triplets.
The solution transmits fetal and maternal vital signs information to a monitor through the base station, and from there, patient information will be transferred to the Philips IntelliSpace Perinatal information management system.
The system tracks medical information across the obstetrical care continuum, from the first antepartum visit to delivery, postpartum, newborn record, discharge and postpartum follow-up visits.
Image: Philips receives FDA approval for its latest Avalon CL Fetal Monitoring solution. Photo: courtesy of PRNewswire/ Royal Philips.